Amgen recognised for development of novel therapies

Amgen’s capacity to provide support to its staff has been underscored as its executive vice-president of research and development Dr Roger Perlmutter received recognition for his work in the discovery and development of novel therapies.

The pharmaceutical organisation explained that Dr Perlmutter, who secured his position at the firm in 2001 as its head of research and development, has led Amgen’s efforts to create a “robust” product pipeline.

Amgen explained that its range of offerings is focused on novel therapeutics to tackle serious conditions.

The firm said: “Amgen’s pipeline includes potential new treatments for cancer, asthma, diabetes, cardiovascular disease and many other life-threatening conditions.”

Dr Perlmutter, who has previously worked for Merck, was elected as a 2009 Fellow of the American Association for the Advancement of Science.

This news comes after Amgen noted that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for the marketing authorisation of the osteoporosis drug Prolia (denosumab).